Oncotelic’s AI Platform Cuts Drug Development Time to 2 Years
Event summary
- Oncotelic’s PDAOAI™ platform will be featured in Qdrant Vector Space Day 2026 keynote on June 11, 2026.
- PDAOAI indexes 28 million PubMed abstracts on Qdrant, using hybrid search and HNSW indexing for biomedical knowledge retrieval.
- Oncotelic advanced two drug candidates from concept to IND filing in 24 months using PDAOAI.
- Introduced ‘manifold folding’ technique to reduce LLM hallucination and improve search precision.
The big picture
Oncotelic’s PDAOAI platform exemplifies the growing trend of AI-driven efficiency in drug discovery, potentially disrupting traditional R&D timelines. The partnership with Qdrant highlights the increasing reliance on vector search technology for handling large-scale biomedical data. If successful, this approach could set a new benchmark for cost and time efficiency in the biotech industry.
What we're watching
- Execution Risk
- Whether Oncotelic can sustain the accelerated drug development timeline for future candidates.
- Technological Scalability
- The pace at which manifold folding and shell sampling techniques can be adopted by other biotech firms.
- Market Differentiation
- How Oncotelic’s cost and time compression will impact competitive positioning in immuno-oncology.
Related topics